Dilution for Nebulised N-Acetylcysteine
For nebulised N-acetylcysteine, use the 20% solution diluted with 0.9% sodium chloride (or sterile water) to achieve a final volume of 2-4.5 mL, or use the 10% solution undiluted at 2-20 mL per dose. 1
Standard Dosing and Dilution Protocol
For Face Mask, Mouthpiece, or Tracheostomy:
20% Solution (most common):
- Dose: 3-5 mL of 20% solution, 3-4 times daily 1
- Can range from 1-10 mL every 2-6 hours depending on severity
- May be diluted with 0.9% sodium chloride or sterile water if needed
10% Solution:
- Dose: 6-10 mL of 10% solution, 3-4 times daily 1
- Can range from 2-20 mL every 2-6 hours
- Use undiluted 1
Target Nebuliser Chamber Volume:
- Most nebulisers require 2.0-4.5 mL total volume 2
- Modern nebulisers leave only 0.5 mL residual, so starting with 2-2.5 mL is sufficient 2
Critical Safety Considerations
Bronchoconstriction Risk:
Always pretreat with a β-agonist bronchodilator before N-acetylcysteine nebulisation 2. This is essential because:
- NAC can cause significant bronchoconstriction 3
- Risk of bronchospasm is well-documented 4
- Pretreatment with salbutamol or similar bronchodilator is mandatory
Equipment Requirements:
- Never use water alone as diluent - it may cause bronchoconstriction when nebulised 2
- Use 0.9% sodium chloride (normal saline) as the preferred diluent 2, 1
- Avoid reactive metals (iron, copper) and rubber in nebuliser equipment 1
- Use glass, plastic, aluminum, or stainless steel components 1
Gas Flow Parameters:
- Flow rate: 6-8 L/min for optimal particle size (2-5 μm) 2
- Use compressed air or electrical compressor (not oxygen unless specifically indicated) 2
- Nebulisation time: typically 10 minutes for bronchodilators, may be longer for mucolytics 2
Storage and Preparation
- Prepare dilutions freshly and use within 1 hour 1
- Unopened vials: store per manufacturer instructions
- Opened vials: refrigerate and use within 96 hours 1
- No antimicrobial preservative present - minimize contamination 1
Evidence Quality Note
The primary evidence comes from FDA drug labeling 1 and British Thoracic Society guidelines 2, which provide the most authoritative dosing recommendations. However, recent research shows conflicting efficacy: while one 2024 study showed improvement in phlegm symptoms in COPD 5, a 2015 study found NAC no more effective than normal saline nebulisation in mechanically ventilated patients 6. The 2010 European guidelines note that NAC may cause bronchoconstriction and recommend against its use in pediatric intensive care pending further evidence 7.
The dilution protocol is well-established, but the clinical benefit of nebulised NAC remains controversial compared to simple saline nebulisation.